{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=4&sponsor=BeiGene", "query": { "sponsor": "BeiGene", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 77, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=5&sponsor=BeiGene&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=BeiGene&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T16:38:00.518Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03336333", "title": "A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2017-10-31", "completion_date": "2027-10-31", "has_results": true, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-10-08T16:38:00.518Z", "location_count": 18, "location_summary": "Augusta, Georgia • Chicago, Illinois • Boston, Massachusetts + 13 more", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03336333" }, { "nct_id": "NCT03712930", "title": "Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer (mCRPC)", "Homologous Recombination Deficiency (HRD)" ], "interventions": [ { "name": "Pamiparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 13, "start_date": "2019-02-05", "completion_date": "2020-09-02", "has_results": true, "last_update_posted_date": "2021-11-17", "last_synced_at": "2026-10-08T16:38:00.518Z", "location_count": 3, "location_summary": "Athens, Georgia • The Bronx, New York • Seattle, Washington", "locations": [ { "city": "Athens", "state": "Georgia" }, { "city": "The Bronx", "state": "New York" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03712930" }, { "nct_id": "NCT05014815", "title": "Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)", "Nonsmall Cell Lung Cancer, Stage IIIB", "Nonsmall Cell Lung Cancer, Stage IV" ], "interventions": [ { "name": "Ociperlimab", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 272, "start_date": "2021-11-16", "completion_date": "2024-09-04", "has_results": true, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-10-08T16:38:00.518Z", "location_count": 11, "location_summary": "Los Angeles, California • Iowa City, Iowa • Las Vegas, Nevada + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "New Hyde Park", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05014815" }, { "nct_id": "NCT04551898", "title": "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "BGB-DXP593", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 181, "start_date": "2020-12-02", "completion_date": "2021-05-25", "has_results": true, "last_update_posted_date": "2024-10-26", "last_synced_at": "2026-10-08T16:38:00.518Z", "location_count": 11, "location_summary": "DeLand, Florida • Hollywood, Florida • Miami, Florida + 5 more", "locations": [ { "city": "DeLand", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04551898" }, { "nct_id": "NCT03749187", "title": "BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "IDH1 Gene Mutation", "IDH2 Gene Mutation", "Low Grade Glioma", "Malignant Glioma", "Recurrent Glioblastoma", "Recurrent WHO Grade II Glioma", "Recurrent WHO Grade III Glioma", "WHO Grade II Glioma", "WHO Grade III Glioma" ], "interventions": [ { "name": "PARP Inhibitor BGB-290", "type": "DRUG" }, { "name": "Temozolomide (TMZ)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "13 Years to 39 Years" }, "enrollment_count": 78, "start_date": "2019-04-03", "completion_date": "2029-07-30", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-10-08T16:38:00.518Z", "location_count": 11, "location_summary": "Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03749187" }, { "nct_id": "NCT04382586", "title": "Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19 Pulmonary Complications", "COVID-19" ], "interventions": [ { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Supportive Care", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2020-07-06", "completion_date": "2021-02-01", "has_results": true, "last_update_posted_date": "2024-10-26", "last_synced_at": "2026-10-08T16:38:00.518Z", "location_count": 10, "location_summary": "Fullerton, California • Washington D.C., District of Columbia • Thomasville, Georgia + 6 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Thomasville", "state": "Georgia" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04382586" }, { "nct_id": "NCT05909904", "title": "A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Head and Neck Cancer" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "BGB-A425", "type": "DRUG" }, { "name": "LBL-007", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2023-08-02", "completion_date": "2026-07-23", "has_results": true, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-08T16:38:00.518Z", "location_count": 9, "location_summary": "Los Angeles, California • Stanford, California • Lone Tree, Colorado + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05909904" }, { "nct_id": "NCT05387668", "title": "Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "BGB-23339", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 0, "start_date": "2022-02-17", "completion_date": "2022-10-17", "has_results": false, "last_update_posted_date": "2022-12-16", "last_synced_at": "2026-10-08T16:38:00.518Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT05387668" }, { "nct_id": "NCT03561298", "title": "A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Subjects" ], "interventions": [ { "name": "BGB-3111 and Drug Cocktail", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "MALE", "summary": "18 Years to 60 Years · Male only" }, "enrollment_count": 18, "start_date": "2018-06-07", "completion_date": "2018-07-02", "has_results": false, "last_update_posted_date": "2019-11-04", "last_synced_at": "2026-10-08T16:38:00.518Z", "location_count": 1, "location_summary": "Daytona Beach, Florida", "locations": [ { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03561298" }, { "nct_id": "NCT05844111", "title": "A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "[14C]-BGB-11417", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "18 Years to 65 Years · Male only" }, "enrollment_count": 6, "start_date": "2023-05-22", "completion_date": "2023-06-18", "has_results": false, "last_update_posted_date": "2025-04-17", "last_synced_at": "2026-10-08T16:38:00.518Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05844111" } ] }